metaLead Therapeutics ApS: Financial statements 2025
CVR: 44212765
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
metaLead Therapeutics ApS (CVR 44212765) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -1,059,149 and a net result of DKK -1,374,975. Equity in the 2025 report amounted to DKK -4,132,623. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,059,149
- Profit/Loss
- DKK -1,374,975
- Equity
- DKK -4,132,623
- Total Assets
- DKK 336,151
- Employees
- 1
Official annual report
How creditworthy is metaLead Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
MetaLead Therapeutics ApS has published its interim report for the period August 2, 2023 to December 31, 2024.
As of March 6, 2025, Emilie Déjean has stepped down as director of metaLead Therapeutics ApS.
About metaLead Therapeutics ApS
metaLead Therapeutics ApS is a Danish company of the type Anpartsselskab based in Taastrup, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michal Mazal Shoshan. The company is owned by metaLead Therapeutics AG. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -1,059,149 and a net result of DKK -1,374,975. Equity in the 2025 report amounted to DKK -4,132,623.
